Previous close | 290.86 |
Open | 275.83 |
Bid | 0.00 x 1200 |
Ask | 0.00 x 3000 |
Day's range | 268.92 - 286.65 |
52-week range | 261.59 - 473.50 |
Volume | |
Avg. volume | 206,346 |
Market cap | 8.009B |
Beta (5Y monthly) | 0.88 |
PE ratio (TTM) | N/A |
EPS (TTM) | -21.81 |
Earnings date | 07 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 409.80 |
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
HERCULES, Calif., April 18, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Bio-Rad Laboratories...